New hope for tough prostate cancer: first human trial launches

NCT ID NCT06879041

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Feb 18, 2026 · Last updated May 19, 2026 · Updated 16 times

Summary

This early-stage study tests a new drug called AZD2284 (and related compounds) in people with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goal is to check safety and find the right dose. About 136 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
NOT_YET_RECRUITING

Palo Alto, California, 94304, United States
Research Site
NOT_YET_RECRUITING

San Diego, California, 92103, United States
Research Site
RECRUITING

Miami, Florida, 33165, United States
Research Site
RECRUITING

Tampa, Florida, 33612, United States
Research Site
RECRUITING

Chicago, Illinois, 60637, United States
Research Site
NOT_YET_RECRUITING

Metairie, Louisiana, 70006, United States
Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
NOT_YET_RECRUITING

Rochester, Minnesota, 55902, United States
Research Site
RECRUITING

Omaha, Nebraska, 68130, United States
Research Site
NOT_YET_RECRUITING

New York, New York, 10032, United States
Research Site
NOT_YET_RECRUITING

Cleveland, Ohio, 44195, United States
Research Site
NOT_YET_RECRUITING

Portland, Oregon, 97239, United States
Research Site
RECRUITING

East Melbourne, 3002, Australia
Research Site
NOT_YET_RECRUITING

CapeTown, 7925, South Africa
Research Site
WITHDRAWN

Durban, 4013, South Africa
Research Site
NOT_YET_RECRUITING

Pretoria, 181, South Africa

Conditions

Explore the condition pages connected to this study.

METASTATIC CASTRATION RESISTANT PROSTATE CANCER